Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 214 Results

January 5, 2015

Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva’s MIN-301 Compound Improves Symptoms of Parkinson’s Disease in Primates

December 3, 2014

Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program

November 25, 2014

Minerva Neurosciences Appoints Dr. Remy Luthringer as CEO

November 13, 2014

Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit

November 6, 2014

Minerva Neurosciences Reports Third Quarter 2014 Financial Results

October 30, 2014

Minerva Neurosciences to Host Third Quarter 2014 Financial Results Webcast and Conference Call

September 22, 2014

Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial

August 28, 2014

Minerva Neurosciences to Present at Baird 2014 Health Care Conference

August 18, 2014

Mark S. Levine Joins Minerva Neurosciences as VP and General Counsel

August 7, 2014

Minerva Neurosciences Reports Second Quarter 2014 Financial Results

«...18 19 202122

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top